• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    ACELYRIN, INC. Announces Positive Phase 3 Data for Izokibep in Hidradenitis Suppurativa; Focuses Strategy on Lonigutamab and Reports Second Quarter 2024 Financial Results

    8/13/24 4:00:00 PM ET
    $SLRN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SLRN alert in real time by email

    Phase 3 trial of izokibep in hidradenitis suppurativa met primary endpoint of HiSCR75 at 12 weeks

    Company to prioritize development of lonigutamab; dose confirmation ongoing in Phase 2 trial with plans to initiate Phase 3 program in Q1 2025

    Cash, cash equivalents, and short-term marketable securities at June 30, 2024 of $635.2 million; projected to extend cash runway to mid-2027

    Company to hold webcast and conference call at 5:00pm ET today

    LOS ANGELES, Aug. 13, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that the Phase 3 trial of izokibep in Hidradenitis Suppurativa (HS) achieved its primary endpoint of HiSCR75 at 12 weeks, as well as a refocused pipeline strategy that prioritizes lonigutamab in thyroid eye disease (TED) and is projected to extend cash runway.

    "While today's positive HS data and previously announced psoriatic arthritis (PsA) data support a path to approval for izokibep, we have determined that a program of this breadth and size is best brought to market by a larger organization with the resources and existing footprint in these indications," said Mina Kim, Chief Executive Officer of ACELYRIN. "We remain excited by the opportunity for lonigutamab to address unmet needs of patients with TED. Consistent with our commitment to disciplined capital allocation, we have decided to focus our efforts toward rapidly advancing lonigutamab through late-stage development with our existing cash resources. Combined with a reduction in force, this strategic shift allows us to extend our cash runway to mid-2027 and fully fund both Phase 3 trials for lonigutamab."

    Izokibep

    In the global Phase 3 trial in HS, izokibep demonstrated statistically significant responses across multiple efficacy endpoints at 12 weeks, including 33% of patients receiving izokibep 160mg weekly (QW) achieving HiSCR75, compared to 21% receiving placebo (p-value=0.0294). In higher order endpoints, 25% of patients achieved HiSCR90, compared to 9% on placebo (p-value=0.0009), and 22% of patients achieved HiSCR100, compared to 8% on placebo (p-value=0.001).

    While the primary endpoint was measured at 12 weeks, ACELYRIN has continued dosing patients in a placebo-controlled manner through week 16. The Company has data from two-thirds of patients at week 16 and the preliminary data demonstrate continued deepening of HiSCR responses over time.

    No new safety signals for izokibep were observed. The most common adverse events were mild-to-moderate injection site reactions, headache, nasopharyngitis, fatigue and diarrhea. Notably, there were no cases of candida infection, liver toxicity or suicidal ideation/behavior in the izokibep treatment arm.

    ACELYRIN will complete the on-going PsA and HS trials, but will suspend new investment in these indications. The ongoing Phase 2b/3 trial of izokibep in uveitis will continue through its primary endpoint, with top line data expected in the fourth quarter of 2024.

    Lonigutamab

    ACELYRIN has completed the Phase 1 proof-of-concept portion of the ongoing lonigutamab trial and the dose-ranging Phase 2 portion in TED patients is continuing. This Phase 2 trial is testing different doses and dose regimens with a goal of establishing a minimum effective dose and enabling selection of the optimal dose and dose regimen for the Phase 3 program. Dose administration every three or four weeks is now being tested.

    With this dose ranging experience in hand, ACELYRIN plans to forgo the originally planned Phase 2b/3 trial design and move directly into a Phase 3 program, potentially with concurrent trials, which is anticipated to be initiated in the first quarter of 2025. The Company will hold an EOP2 meeting with the FDA later this year and thereafter host an investor presentation to provide additional Phase 2 data and details for the planned Phase 3 program.

    "ACELYRIN has taken a patient-centered approach to developing lonigutamab, being the first company to conduct dose exploration work with a subcutaneous anti-IGF-1R treatment in patients with Thyroid Eye Disease," said Shoaib Ugradar, MD, Department of Orbital and Oculoplastic Surgery, private practice, Beverly Hills, California. "I am encouraged by this approach and look forward to participating in the pivotal trials."

    SLRN-517

    ACELYRIN has completed a single ascending dose study of SLRN-517, the Company's early anti-C-KIT program, in healthy volunteers and has stopped further development of this program.

    Corporate Reorganization

    Aligned with the Company's prioritization of lonigutamab and associated strategic shifts for izokibep and SLRN-517, ACELYRIN is completing an approximately 33% reduction in its workforce.

    "I want to thank our colleagues who will be departing from ACELYRIN as part of the restructuring and acknowledge their many contributions to the development of izokibep, and to the evolution of our company. We wish them the very best in the future," added Ms. Kim.

    The Company expects these combined efforts will extend cash runway to mid-2027, guidance which includes both the financial impact of the corporate reorganization and clinical program reprioritization. Specifically, the Company's existing cash resources are expected to fund the ongoing Phase 2 trial and two planned registrational Phase 3 trials for lonigutamab in TED, the on-going izokibep Phase 3 trial in uveitis, and the completion of the ongoing izokibep HS and PsA trials.

    Q2 2024 Financial Highlights

    Cash Position: Cash, cash equivalents and short-term marketable securities totaled $635.2 million at June 30, 2024. The Company expects these to fund operations to mid-2027.

    R&D Expenses: Research and development expenses were $76.4 million for the second quarter as compared to $30.0 million for the same period in 2023. The increases were primarily a result of additional clinical development activity across the pipeline and a $14.3 million expense related to the termination of a supply agreement.

    G&A Expenses: General and administrative expenses were $16.6 million for the second quarter as compared to $12.7 million for the same period in 2023. The expenses include stock-based compensation expense of $5.3 million, which decreased from $7.2 million for the same quarter in 2023.

    Net Loss: Net loss for the quarter ended June 30, 2024 was $85.7 million, compared to $26.0 million for the same period in 2023.

    Webcast and Conference Call Information

    ACELYRIN will host a conference call and webcast today, August 13, 2024, at 5:00pm ET to discuss these announcements. A live webcast of the conference call can be accessed in the "Events & Presentations" section of ACELYRIN's website at www.acelyrin.com. A recording of the webcast will be available and archived on the Company's website for approximately 30 days.

    Upcoming Investor Presentations

    ACELYRIN management will participate in webcasted presentations and 1x1 meetings at several upcoming investor conferences including the 2024 Wells Fargo Healthcare Conference, the 22nd Annual Morgan Stanley Global Healthcare Conference and the H.C. Wainwright 26th Annual Global Investment Conference.

    About Lonigutamab

    Lonigutamab is a humanized IgG1 monoclonal antibody targeting the IGF-1 receptor and is delivered subcutaneously. Relative to standard of care, lonigutamab binds to a distinct epitope, which results in internalization of the receptor within minutes, and in preclinical binding and functional laboratory assays, it has been shown to be 75-fold more potent. The characteristics of lonigutamab that enable subcutaneous delivery also enable the potential for longer-term, convenient dosing, which can potentially improve depth and durability of clinical response.

    About Izokibep

    Izokibep is a small protein therapeutic designed to inhibit IL-17A with high potency through tight binding affinity, the potential for robust tissue penetration due to its small molecular size, about one-tenth the size of a monoclonal antibody, and an albumin binding domain that extends half-life. Clinical trial data supports the hypothesis that these unique characteristics of izokibep may provide clinically meaningful and differentiated benefits for patients, including resolution of key manifestations of disease. The late-stage izokibep PsA and HS data have demonstrated levels of clinical response comparable with next generation approaches to IL-17 inhibition. These data also demonstrate that targeting IL-17A alone with greater potency can achieve the same or better clinical responses than agents targeting IL-17 subunits more broadly than IL-17A, without their associated safety liabilities. Izokibep is currently being evaluated in multiple late-stage trials in moderate-to-severe hidradenitis suppurativa (HS), moderate-to-severe psoriatic arthritis (PsA), and noninfectious uveitis.

    About ACELYRIN, INC.

    ACELYRIN, INC. (NASDAQ:SLRN) is focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating the development and commercialization of transformative medicines. ACELYRIN's lead program, lonigutamab, is a subcutaneously delivered monoclonal antibody targeting IGF-1R being investigated for the treatment of thyroid eye disease.

    For more information about ACELYRIN, visit us at www.acelyrin.com or follow us on LinkedIn and X.

    Forward Looking Statements

    This press release contains forward-looking statements including, but not limited to, statements related to the overall advancement of ACELYRIN's programs and ability to accelerate the development and delivery of transformative medicines; the therapeutic potential of ACELYRIN's product candidates; ACELYRIN's ability to address unmet needs of patients with thyroid eye disease (TED) anticipated development activities including the planned initiation of Phase 3 trials in TED and the ability for such trials to serve as registrational studies, anticipated cash runway guidance to mid-FY2027, and the ability for such funds to support development of lonigutamab through both Phase 3 trials, plans to continue the ongoing izokibep Phase 2b/3 trial in psoriatic arthritis and the ongoing izokibep Phase 3 trial in hidradenitis suppurativa; the anticipated timing and availability of clinical data from the ongoing izokibep Phase 2b/3 trial in uveitis; and other statements that are not historical fact. These forward-looking statements are based on ACELYRIN's current plans, objectives and projections, and are inherently subject to risks and uncertainties that may cause ACELYRIN's actual results to materially differ from those anticipated in such forward-looking statements. Such risks and uncertainties include, without limitation, those associated with the successful completion of development and regulatory activities with respect to ACELYRIN's product candidates, the risk that future results could differ materially and adversely from early clinical data, the risk that preliminary week 16 data of the Phase 3 trial in HS is not indicative of any future, final week 16 data in such trial, and other risks and uncertainties affecting ACELYRIN including those described from time to time under the caption "Risk Factors" and elsewhere in ACELYRIN's current and future reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this press release are made as of this date, and ACELYRIN undertakes no duty to update such information except as required under applicable law.

    ACELYRIN, Inc.
    Condensed Consolidated Statement of Operations and Comprehensive Loss
    (in thousands, except share and per share data)
    (unaudited)
              
       Six months ended June 30, Six months ended June 30,
        2024   2023   2024   2023 
              
    Operating expenses       
     Research and development$76,382  $30,030  $134,414  $197,950 
     General and administrative$16,643  $12,666  $41,385  $24,579 
      Total operating expenses 93,025   42,696   175,799   222,529 
    Loss from operations (93,025)  (42,696)  (175,799)  (222,529)
     Change in fair value of derivative liability -   10,144   -   10,291 
     Interest income 8,447   6,685   17,597   9,984 
     Other income (expense), net (1,094)  (172)  37,557   (235)
    Net loss (85,672)  (26,039)  (120,645)  (202,489)
    Other comprehensive gain/(loss)       
     Unrealized gain (loss) on short-term marketable securities, net (62)  44   (329)  130 
      Total other comprehensive gain (loss) (62)  44   (329)  130 
    Net loss and other comprehensive loss$(85,734) $(25,995) $(120,974) $(202,359)
    Net loss per share attributable to common stockholders, basic and diluted$(0.86) $(0.40) $(1.22) $(4.71)
    Weighted-average common shares outstanding, basic and diluted 99,161,710   65,210,117   98,537,685   42,974,640 



    ACELYRIN, INC.
    Selected Consolidated Balance Sheet Data
    (unaudited)
    (in thousands)
     June 30, December 31,
      2024   2023 
    Cash and cash equivalents$128,211  $218,097 
    Short-term marketable securities 507,029   503,229 
    Total assets 651,739   742,690 
    Total liabilities 83,521   86,353 
    Accumulated deficit (609,364)  (488,719)
            

    ACELYRIN Contact:

    Tyler Marciniak

    Vice President of Investor Relations and Corporate Affairs

    [email protected]

    [email protected]



    Primary Logo

    Get the next $SLRN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SLRN

    DatePrice TargetRatingAnalyst
    8/14/2024$18.00 → $6.00Buy → Neutral
    H.C. Wainwright
    7/8/2024$13.00Equal Weight → Overweight
    Wells Fargo
    12/13/2023$11.00Equal Weight
    Wells Fargo
    12/8/2023$8.00Neutral
    Citigroup
    9/13/2023$19.00Overweight → Equal-Weight
    Morgan Stanley
    9/5/2023$44.00Buy
    H.C. Wainwright
    5/30/2023Overweight
    Morgan Stanley
    5/30/2023$31.00Buy
    Jefferies
    More analyst ratings

    $SLRN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Alumis Stockholders Approve Merger with ACELYRIN

      SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today announced that its stockholders voted to approve all proposals required to be approved in connection with the pending merger with ACELYRIN, INC. (NASDAQ:SLRN) at its Special Meeting of Stockholders. Martin Babler, President, Chief Executive Officer and Chairman of Alumis, said, "We thank our stockholders for their support for the merger and with this milestone now complete, we are moving expeditious

      5/13/25 1:00:00 PM ET
      $ALMS
      $SLRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

      LOS ANGELES, May 13, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, Inc. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that at the Company's special meeting of stockholders held earlier today, its stockholders voted to approve the adoption of the Company's merger agreement with Alumis Inc. (NASDAQ:ALMS). As previously announced, under the terms of the amended merger agreement, ACELYRIN stockholders will receive 0.4814 shares of Alumis common stock for each share of ACELYRIN common stock owned at the closing of the transaction. "We appreciate our stockholders' support for our merger

      5/13/25 1:00:00 PM ET
      $ALMS
      $SLRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote "FOR" the Proposed Transaction with Alumis

      ACELYRIN Urges Stockholders to Vote FOR the Proposed Transaction Today LOS ANGELES, May 06, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that leading independent proxy advisory firm Institutional Shareholder Services ("ISS") has recommended that ACELYRIN stockholders vote "FOR" the proposed merger ("Proposed Transaction") of the Company with Alumis Inc. (NASDAQ:ALMS). The Company's special meeting of stockholders to vote on the Proposed Transaction is scheduled for May 13, 2025. ACELYRIN urges its stockholders to vote FOR the Pr

      5/6/25 4:30:00 PM ET
      $ALMS
      $SLRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLRN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Ayurmaya Capital Management Company, Lp returned 9,334,735 shares to the company (SEC Form 4)

      4 - ACELYRIN, Inc. (0001962918) (Issuer)

      5/23/25 4:23:20 PM ET
      $SLRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Kim Mina was granted 89,526 shares and returned 770,833 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - ACELYRIN, Inc. (0001962918) (Issuer)

      5/23/25 4:11:54 PM ET
      $SLRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Cozadd Bruce C

      4 - ACELYRIN, Inc. (0001962918) (Issuer)

      5/23/25 4:11:07 PM ET
      $SLRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLRN
    Leadership Updates

    Live Leadership Updates

    See more
    • Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million

      Avalo acquires Phase 2-ready anti-IL-1β mAb, AVTX-009, through acquisition of AlmataBio, Inc. Topline results from planned Phase 2 trial in hidradenitis suppurativa expected in 2026Executed private placement financing of up to $185 million, including initial upfront investment of $115.6 million; expected to extend cash runway into 2027 Webcast to be held tomorrow, March 28, 2024 at 8:30 a.m. E.T. WAYNE, Pa. and ROCKVILLE, Md., March 27, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX) today announced it has acquired a Phase 2-ready anti-IL-1β mAb, which it refers to as AVTX-009, through the acquisition of privately held AlmataBio, Inc. Concurrent with the acquisition, Ava

      3/27/24 4:01:00 PM ET
      $AVTX
      $SLRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ACELYRIN, INC. Appoints Agnes Lee as Senior Vice President, Investor Relations and Corporate Communications

      Highly accomplished leader bringing more than 25 years of investor relations, communications, and operational & strategic finance experience at public healthcare companies LOS ANGELES, Feb. 15, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced the appointment of Agnes Lee as Senior Vice President, Investor Relations and Corporate Communications. Reporting to Founder and CEO Shao-Lee Lin, MD, PhD, Ms. Lee will be responsible for leading investor relations and corporate communications and will join the company's Senior Leadership Team.

      2/15/24 4:05:00 PM ET
      $SLRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ACELYRIN, INC. Appoints Lynn Tetrault to Board of Directors

      LOS ANGELES, Dec. 20, 2023 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced the appointment of Lynn Tetrault to its board of directors. "I am pleased to welcome Lynn to our board of directors as we close our first year as a publicly traded company. Lynn is a highly accomplished biopharma executive and her extensive expertise spanning global human capital strategy, talent management, business operations, and corporate affairs adds a valuable dimension to support our evolving company," said Shao-Lee Lin, MD, PhD, Founder and CEO of ACELYRIN

      12/20/23 4:30:00 PM ET
      $SLRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLRN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ACELYRIN downgraded by H.C. Wainwright with a new price target

      H.C. Wainwright downgraded ACELYRIN from Buy to Neutral and set a new price target of $6.00 from $18.00 previously

      8/14/24 7:48:43 AM ET
      $SLRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ACELYRIN upgraded by Wells Fargo with a new price target

      Wells Fargo upgraded ACELYRIN from Equal Weight to Overweight and set a new price target of $13.00

      7/8/24 8:17:02 AM ET
      $SLRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wells Fargo initiated coverage on ACELYRIN with a new price target

      Wells Fargo initiated coverage of ACELYRIN with a rating of Equal Weight and set a new price target of $11.00

      12/13/23 8:08:18 AM ET
      $SLRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLRN
    Financials

    Live finance-specific insights

    See more
    • ACELYRIN Adopts Limited-Duration Stockholder Rights Plan

      LOS ANGELES, March 13, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that, in response to Tang Capital Partners' continued rapid accumulation of 8.8% of ACELYRIN'S outstanding common stock, its Board of Directors has approved the adoption of a limited-duration stockholder rights plan ("Rights Plan"). The ACELYRIN Board and management team continue to engage with stockholders and are focused on maximizing stockholder value. Pursuant to the Rights Plan, the Company is issuing one right for each share of common stock as of the close

      3/13/25 7:00:00 AM ET
      $SLRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

      Topline data from Phase 3 ONWARD trials for Alumis' ESK-001 in moderate-to-severe plaque psoriasis on track for readout in first half of 2026; Topline data from Phase 2b LUMUS trial in systemic lupus erythematosus on track for readout in 2026 Evaluation underway of development plan for ACELYRIN's lonigutamab to confirm differentiation in a capital efficient manner Pro forma cash position of approximately $737 million as of December 31, 2024, provides runway into 2027, beyond expected multiple clinical readouts for highly differentiated late-stage portfolio Alumis and ACELYRIN stockholders to own ~55% and ~45%, respectively, of combined company on a fully diluted basis Combined company wi

      2/6/25 4:15:00 PM ET
      $ALMS
      $SLRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ACELYRIN, INC. Announces Additional Phase 2 Data and Phase 3 Program Design for Lonigutamab in Thyroid Eye Disease

      Totality of data observed with subcutaneous lonigutamab in Thyroid Eye Disease (TED) patients demonstrate potential for efficacy in line with standard of care and a more favorable safety profile Conducted positive end of Phase 2 FDA meeting; Phase 3 program expected to be initiated in Q1 2025 Topline Phase 3 data expected in second half of 2026; cash runway expected through mid-2027 Conference call to review unmet need in TED, new Phase 2 data and Phase 3 program design to be held today, January 6, 2025, at 4:30 PM ET LOS ANGELES, Jan. 06, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery

      1/6/25 4:00:00 PM ET
      $SLRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLRN
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13D/A filed by ACELYRIN INC.

      SCHEDULE 13D/A - ACELYRIN, Inc. (0001962918) (Subject)

      5/23/25 4:15:26 PM ET
      $SLRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13D/A filed by ACELYRIN INC.

      SCHEDULE 13D/A - ACELYRIN, Inc. (0001962918) (Subject)

      5/23/25 4:01:03 PM ET
      $SLRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by ACELYRIN INC.

      EFFECT - ACELYRIN, Inc. (0001962918) (Filer)

      5/23/25 12:15:04 AM ET
      $SLRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLRN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by ACELYRIN INC.

      SC 13G/A - ACELYRIN, Inc. (0001962918) (Subject)

      11/14/24 1:28:35 PM ET
      $SLRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by ACELYRIN INC.

      SC 13G/A - ACELYRIN, Inc. (0001962918) (Subject)

      11/12/24 12:13:00 PM ET
      $SLRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by ACELYRIN INC.

      SC 13G - ACELYRIN, Inc. (0001962918) (Subject)

      11/4/24 10:56:23 AM ET
      $SLRN
      Biotechnology: Pharmaceutical Preparations
      Health Care